Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression

JAMA

Volumn 296, Issue 7, 2006, Pages 806-814

  Swindells, Susan ^a   DiRienzo, A Gregory ^b   Wilkin, Timothy ^c   Fletcher, Courtney V ^d   Margolis, David M ^f   Thal, Gary D ^g   Godfrey, Catherine ^h   Bastow, Barbara ⁱ   Ray, M Graham ^e   Wang, Hongying ^b   Coombs, Robert W ^j   McKinnon, John ^k   Mellors, John W ^k  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d UNIVERSITY OF COLORADO   (United States)

^e UNIVERSITY OF COLORADO   (United States)

^f UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^g BRISTOL MYERS SQUIBB   (United States)

^h NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

ⁱ AIDS Clinical Trial Group Operations Center   (United States)

^j UNIVERSITY OF WASHINGTON   (United States)

^k UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; RITONAVIR;

ADULT; AGED; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAINTENANCE THERAPY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UNITED STATES;

EID: 33747132954     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.296.7.806     Document Type: Article

References (27)

1. Wafaa El-Sadr, Neaton J; the SMART Study Investigators. Episodic CD4-guided use of ART is inferior to continuous therapy: results of the SMART Study [abstract 106LB]. Presented at: 13th Conference on Retroviruses and Opportunistic Infections; February 7, 2006; Denver, Colorado.
2. Dybul M, Chun TW, Yoder C, et al. Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: effects on virologic, immunologic, and toxicity parameters. Proc Natl Acad Sci U S A. 2001;98:15161-15166.
3. Ananworanich J, Nuesch R, Le Braz M, et al. Failures of 1 week on, 1 week off antiretroviral therapies in a randomized trial. AIDS. 2003;17:F33-F37.
4. Havlir DV, Marschner IC, Hirsch MS, et al; AIDS Clinical Trials Group Study 343 Team. Maintenance antiretroviral therapies in HIV infected patients with undetectable plasma HIV-1 RNA after triple-drug therapy. N Engl J Med. 1998;339:1261-1268.
5. Pialoux G, Raffi F, Brun-Vezinet F, et al; Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team. A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. N Engl J Med. 1998;339:1269-1276.
6. Reijers MH, Weverling GJ, Jurriaans S, et al. Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study. Lancet. 1998;352:185-190.
7. Kahlert C, Hupfer M, Wagels T, et al. Ritonavir boosted indinavir as a simplified maintenance "mono"-therapy for HIV infection. AIDS. 2004;18:955-957.
8. Arribas JR, Pulido F, Delgado R, et al. Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study). J Acquir Immune Defic Syndr. 2005;40:280-287.
9. Vernazza P, Daneel S, Schiffer V, et al; Swiss Cohort. Viral suppression in CSF and genital tract in ritonavirboosted "atazanavir only" maintenance therapy (ATARITMO-Study) [WeOa0204]. Presented at: 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment; July 24, 2005; Rio de Janeiro, Brazil.
10. Nolan D, Mallal S. Complications associated with NRTI therapy: update on clinical features and possible pathogenic mechanisms. Antivir Ther. 2004;9:849-863.
11. Murphy R, Zhang J, Hafner R, et al. Switching to a thymidine analog-sparing or a nucleoside-sparing regimen improves lipoatrophy: 24-week results of a prospective randomized clinical trial, ACTG 5110 [abstract 45]. Presented at: 12th Conference on Retroviruses and Opportunistic Infections; February 23, 2005; Boston, Mass.
12. Malan N, Krantz E, David N, et al. Efficacy and safety of atazanavir-based therapy in antiretroviral naïve HIV-1 infected subjects, both with and without ritonavir: 48-week results from AI24-089 [abstract 107LB]. Presented at: 13th Conference on Retroviruses and Opportunistic Infections; February 7, 2006; Denver, Colo.
13. Johnson M, Grinsztejn B, Rodriguez C, et al. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS. 2006;20:711-718.
14. Murphy R, Thiry A, Mancini M, et al. Twelve weeks of atazanavir treatment reverses nelfinavir-associated hyperlipidaemia: results from BMS AI424-044. Antivir Ther. 2002;7:L10.
15. Gatell J, Salmon-Ceron D, Lazzarin A, et al; SWAN Study Group. Efficacy and safety of atazanavir (ATV)-based HAART in patients switched from a stable boosted or unboosted protease inhibitor (PI) treatment. Presented at: 10th European AIDS Conference; November 18, 2005; Dublin, Ireland.
16. Chesney MA, Ickovics JR, Chambers DB, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG Adherence Instrument. AIDS Care. 2000;12:255-266.
17. Reyataz [package insert]. Princeton, NJ: Bristol-Myers Squibb Co; October 2004.
18. Toxicity tables . Regulatory Compliance Center Web site. http://rcc.tech-res.com/tox_tables.htm. Accessibility verified July 12, 2006.
19. Zuckerman RA, Whittington WL, Celum CL, et al. Higher concentration of HIV-1 RNA in rectal mucosa secretions than in blood and seminal plasma, among men who have sex with men, independent of antiretroviral therapy. J Infect Dis. 2004;190:156-161.
20. Cox DR, Oakes D. Analysis of Survival Data. London, England: Chapman & Hall; 1984.
21. Lehmann EL. Nonparametrics: Statistical Methods Based on Ranks [Section 1.2]. San Francisco, Calif: Holden-Day; 1975.
22. Leitner T, Foley B, Hahn B, et al. Sequence Compendium HIV. eds Los Alamos, NM: Theoretical Biology and Biophysics Group, Los Alamos National Laboratory; 2005.
23. Vernazza PL, Troiani L, Flepp MJ, et al. Potent antiretroviral treatment of HIV-infection results in suppression of the seminal shedding of HIV: the Swiss HIV Cohort Study. AIDS. 2000;14:117-121.
24. Gunthard HF, Havlir DV, Fiscus S, et al. Residual human immunodeficiency virus (HIV) Type 1 RNA and DNA in lymph nodes and HIV-1 RNA in genital secretions and in cerebrospinal fluid after suppression of viremia for 2 years. J Infect Dis. 2001;183:1318-1327.
25. Busti AJ, Hall RG, Margolis DM. Atazanavir for the treatment of human immunodeficiency virus infection. Pharmacotherapy. 2004;24:1732-1747.
26. Best B, Letendre S, Patel P, et al. Low atazanavir concentrations in cerebrospinal fluid [abstract 576]. Presented at: 13th Conference on Retroviruses and Opportunistic Infections; February 7, 2006; Denver, Colo.
27. Fletcher CV, Testa MA, Brundage RC, et al. Four measures of antiretroviral medication adherence and virologic response in AIDS Clinical Trials Group (ACTG) study 359. J Acquir Immune Defic Syndr. 2005;40:301-306.